Royal Bank of Canada’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.17M | Sell |
17,692
-12,880
| -42% | -$819K | ﹤0.01% | 3508 |
|
|
2025
Q4 | $1.94M | Sell |
30,572
-37,621
| -55% | -$2.34M | ﹤0.01% | 3162 |
|
|
2025
Q3 | $3.75M | Buy |
68,193
+22,302
| +49% | +$919K | ﹤0.01% | 2888 |
|
|
2025
Q2 | $1.51M | Sell |
45,891
-7,656
| -14% | -$266K | ﹤0.01% | 3540 |
|
|
2025
Q1 | $2.15M | Buy |
53,547
+9,422
| +21% | +$433K | ﹤0.01% | 2889 |
|
|
2024
Q4 | $2.08M | Buy |
44,125
+26,999
| +158% | +$1.4M | ﹤0.01% | 3006 |
|
|
2024
Q3 | $904K | Buy |
17,126
+13,946
| +439% | +$777K | ﹤0.01% | 3646 |
|
|
2024
Q2 | $172K | Sell |
3,180
-14,093
| -82% | -$851K | ﹤0.01% | 4880 |
|
|
2024
Q1 | $1.21M | Sell |
17,273
-7,179
| -29% | -$555K | ﹤0.01% | 3300 |
|
|
2023
Q4 | $2.04M | Buy |
24,452
+22,233
| +1,002% | +$805K | ﹤0.01% | 3063 |
|
|
2023
Q3 | $65K | Buy |
2,219
+43
| +2% | +$1.43K | ﹤0.01% | 5627 |
|
|
2023
Q2 | $70K | Sell |
2,176
-4,565
| -68% | -$169K | ﹤0.01% | 5587 |
|
|
2023
Q1 | $237K | Sell |
6,741
-8,285
| -55% | -$338K | ﹤0.01% | 4472 |
|
|
2022
Q4 | $688K | Buy |
15,026
+12,125
| +418% | +$522K | ﹤0.01% | 3815 |
|
|
2022
Q3 | $140K | Sell |
2,901
-2,036
| -41% | -$98K | ﹤0.01% | 5066 |
|
|
2022
Q2 | $194K | Sell |
4,937
-1,870
| -27% | -$75.3K | ﹤0.01% | 4823 |
|
|
2022
Q1 | $250K | Sell |
6,807
-9,965
| -59% | -$354K | ﹤0.01% | 4887 |
|
|
2021
Q4 | $764K | Buy |
16,772
+6,493
| +63% | +$251K | ﹤0.01% | 4086 |
|
|
2021
Q3 | $367K | Buy |
10,279
+1,857
| +22% | +$54.7K | ﹤0.01% | 4607 |
|
|
2021
Q2 | $167K | Sell |
8,422
-9,656
| -53% | -$227K | ﹤0.01% | 5230 |
|
|
2021
Q1 | $421K | Sell |
18,078
-14,953
| -45% | -$319K | ﹤0.01% | 4334 |
|
|
2020
Q4 | $687K | Buy |
33,031
+12,288
| +59% | +$225K | ﹤0.01% | 3854 |
|
|
2020
Q3 | $449K | Buy |
20,743
+2,176
| +12% | +$50.9K | ﹤0.01% | 3951 |
|
|
2020
Q2 | $438K | Sell |
18,567
-959
| -5% | -$18K | ﹤0.01% | 3888 |
|
|
2020
Q1 | $230K | Buy |
19,526
+15,052
| +336% | +$192K | ﹤0.01% | 4226 |
|
|
2019
Q4 | $47K | Buy |
4,474
+3,424
| +326% | +$35.2K | ﹤0.01% | 5485 |
|
|
2019
Q3 | $12K | Sell |
1,050
-1,023
| -49% | -$12.8K | ﹤0.01% | 5701 |
|
|
2019
Q2 | $23K | Buy |
2,073
+7
| +0.3% | +$68 | ﹤0.01% | 5642 |
|
|
2019
Q1 | $17K | Buy |
2,066
+166
| +9% | +$1.22K | ﹤0.01% | 5717 |
|
|
2018
Q4 | $12K | Sell |
1,900
-1,299
| -41% | -$9.53K | ﹤0.01% | 5793 |
|
|
2018
Q3 | $32K | Buy |
3,199
+2,654
| +487% | +$21.3K | ﹤0.01% | 5442 |
|
|
2018
Q2 | $5K | Buy |
545
+504
| +1,229% | +$4.19K | ﹤0.01% | 6024 |
|
|
2018
Q1 | $0 | Sell |
41
-723
| -95% | -$6.2K | ﹤0.01% | 6416 |
|
|
2017
Q4 | $6K | Sell |
764
-16,417
| -96% | -$186K | ﹤0.01% | 6030 |
|
|
2017
Q3 | $250K | Buy |
17,181
+4,075
| +31% | +$55.7K | ﹤0.01% | 4350 |
|
|
2017
Q2 | $159K | Sell |
13,106
-909
| -6% | -$12.6K | ﹤0.01% | 4494 |
|
|
2017
Q1 | $180K | Buy |
14,015
+11,878
| +556% | +$139K | ﹤0.01% | 4399 |
|
|
2016
Q4 | $27K | Buy |
+2,137
| New | +$22.7K | ﹤0.01% | 5598 |
|
|
2015
Q4 | – | Sell |
-1,567
| Closed | -$10K | – | 6670 |
|
|
2015
Q3 | $10K | Sell |
1,567
-375
| -19% | -$2.56K | ﹤0.01% | 5876 |
|
|
2015
Q2 | $13K | Buy |
+1,942
| New | +$12.7K | ﹤0.01% | 5932 |
|
|
2014
Q2 | – | Sell |
-77,990
| Closed | -$476K | – | 5961 |
|
|
2014
Q1 | $741K | Buy |
+77,990
| New | +$705K | ﹤0.01% | 3023 |
|
|
2013
Q4 | – | Sell |
-358
| Closed | -$3K | – | 5962 |
|
|
2013
Q3 | $3K | Buy |
+358
| New | +$3.84K | ﹤0.01% | 5749 |
|
Other funds holding CYTK
VPM
VCM
ACA
Royal Bank of Canada's CYTK Position: Q1 2026 in Review
Royal Bank of Canada reduced its Cytokinetics (CYTK) stake by 42% in Q1 2026, selling an estimated $819K and leaving 17,692 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #3508.
Royal Bank of Canada first reported a position in CYTK in Q3 2013 and has held it in 42 quarters since. The position peaked at $3.75M in Q3 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.
- Royal Bank of Canada held 17,692 shares of Cytokinetics worth $1.17M as of Q1 2026.
- Royal Bank of Canada sold 12,880 Cytokinetics shares in Q1 2026, an estimated $819K.
- Cytokinetics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #3508 holding.
- Royal Bank of Canada first reported a position in Cytokinetics in Q3 2013 and has held it in 42 quarters since.
- Royal Bank of Canada's Cytokinetics position peaked at $3.75M in Q3 2025.
- 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.